Quick answer: in the CJC-1295/ipamorelin vs tesamorelin comparison, only tesamorelin is an FDA-approved drug (Egrifta) backed by phase 3 trials, where 2 mg daily cut deep belly fat by 15.2% in 26 weeks versus a 5.0% rise on placebo.[2][3] CJC-1295 and ipamorelin are unapproved, and no published human study has tested them together.[6][10] Their human data cover hormone levels only.[7]
This guide compares how they work, the evidence, side effects, dosing and legal status. For each one in depth, see our tesamorelin profile, the CJC-1295 and ipamorelin guide and the growth hormone peptides hub.
At a glance
| CJC-1295/ipamorelin | Tesamorelin | |
|---|---|---|
| What it is | Two peptides: a GHRH analog plus a ghrelin mimic | One GHRH analog |
| FDA status | Neither approved | Approved 2010 (Egrifta) |
| Approved use | None | Excess belly fat in adults with HIV and lipodystrophy |
| Largest human trial | Ipamorelin: 114 surgery patients (failed) | 412 patients, 26 weeks |
| Tested together? | No | Not applicable |
| Label dose | None | 1.4 mg (SV) or 1.28 mg (WR) daily |
| Compounding | Advisers voted against both | Brand prescription |
Sources: tesamorelin label and FDA approval records,[1][2] FDA’s reviews of CJC-1295 and ipamorelin[6][9] and the ipamorelin trial.[8]
How each works
All three peptides prompt the pituitary gland to release more of the body’s own growth hormone, which raises IGF-1. They differ in which signal they copy:
- Tesamorelin is the full 44-amino-acid human GHRH with a short fatty chain added at one end.[1]
- CJC-1295 is a modified 29-amino-acid GHRH fragment. The studied version carries a “DAC” attachment that binds to albumin so it lasts about a week; the version usually paired with ipamorelin lacks it.[6][7]
- Ipamorelin is a five-amino-acid peptide that activates the ghrelin receptor. In pigs, it released growth hormone without raising the stress hormones ACTH and cortisol.[11]
Because tesamorelin acts through the pituitary, its label rules it out after pituitary surgery, head radiation or other damage to the hypothalamic-pituitary axis.[1] FDA likewise notes that CJC-1295 results from healthy volunteers may not carry over to people with growth hormone deficiency, since these peptides depend on a working pituitary.[6]
Evidence compared
Tesamorelin has large, placebo-controlled trials:
- Phase 3 trial 1 (412 adults with HIV): deep belly fat fell 15.2% versus a 5.0% rise on placebo; triglycerides fell 50 mg/dL; IGF-1 rose 81%.[3]
- Phase 3 trial 2 (404 adults): deep belly fat fell 10.9% versus 0.6%, reaching about 18% by 12 months. Gains were quickly lost after switching to placebo.[4]
- Fatty liver (61 adults with HIV): liver fat fell 37% relative to placebo over 12 months.[5]
- Obesity without HIV (60 adults with low growth hormone): deep belly fat fell 35 cm² more than placebo over 12 months, without changing blood sugar.[15]
CJC-1295 and ipamorelin have much less:
- CJC-1295 with DAC raised growth hormone and IGF-1 for days in 63 healthy adults, but no study tested any health outcome. A trial in HIV-related belly fat was stopped in 2006 and never published.[6][7]
- Ipamorelin’s only published efficacy trial, for gut recovery after bowel surgery, did not beat placebo.[8]
- A 2026 endocrine review put tesamorelin in its top evidence tier and no-DAC CJC-1295 in its lowest, with no peer-reviewed human studies.[10]
Who each was tested in
The people in a study shape what its results mean for you:
- Tesamorelin: the phase 3 trials enrolled adults with HIV on antiretroviral treatment who had built up excess belly fat; 86% of the first trial’s participants were men.[3] A separate trial enrolled 60 adults with abdominal obesity and low growth hormone but no HIV.[15]
- CJC-1295 with DAC: healthy volunteers aged 21 to 61, about 87% of them men, most of whom received a single injection.[6][7]
- Ipamorelin: healthy men given single IV infusions, and hospital patients recovering from bowel surgery.[8]
None of these groups matches the typical person using CJC-1295/ipamorelin for fitness or anti-aging, and none tested the pair.
What happens after stopping
Tesamorelin’s benefit depends on continued use. In the second phase 3 trial, people switched to placebo after 6 months rapidly lost their visceral fat reduction, while those who stayed on the drug kept it.[4]
For CJC-1295 with DAC, IGF-1 stayed raised for 9 to 11 days after a single injection and then declined toward baseline.[7][6] No study has followed people after stopping ipamorelin or the pair.
Side effects compared
| CJC-1295/ipamorelin (each tested alone) | Tesamorelin (label, 26 weeks) | |
|---|---|---|
| Injection-site reactions | About 70% with CJC-1295 with DAC | 17% vs 6% on placebo |
| Headache | 63% with CJC-1295 with DAC | Not listed in the label table |
| Flushing or low blood pressure | 30% with CJC-1295 with DAC | Flushing listed among allergic-type reactions, which affected 4% |
| Joint pain, swelling | Not reported in short studies | Joint pain 13% vs 11%; leg swelling 6% vs 2% |
| Blood sugar | High blood sugar at discharge 14.3% vs 8.6% (ipamorelin, IV) | HbA1c of 6.5% or higher in 5% vs 1% |
| Raised IGF-1 | Above normal only at the top CJC-1295 dose | 47% had IGF-1 over 2 standard deviations above normal |
Sources: FDA’s reviews of CJC-1295[6] and ipamorelin,[9] and the tesamorelin label.[1]
These numbers come from different people, doses and study lengths, so they cannot be ranked directly. Tesamorelin’s list is longer partly because it was tested in 740 people for up to a year.[1] For more, see CJC-1295 and ipamorelin side effects.
Dosing compared
- Tesamorelin: 1.4 mg once daily for Egrifta SV or 1.28 mg once daily for Egrifta WR, injected into the abdomen. The two products are not interchangeable.[14][1]
- CJC-1295/ipamorelin: no tested dose for the pair. CJC-1295 with DAC was studied at 20 to 250 mcg per kg given a week or more apart, and ipamorelin only by IV.[6][8]
See our tesamorelin dosage and CJC-1295 and ipamorelin dosage guides.
Legal status and access
- Tesamorelin is a prescription drug, approved by FDA on November 10, 2010.[2]
- CJC-1295: FDA’s compounding advisers voted against every CJC-1295 form for traditional pharmacies in December 2024.[12]
- Ipamorelin: the same committee voted 0 to 12, with one abstention, in October 2024.[13]
Which one makes sense?
For an adult with HIV and excess deep belly fat, tesamorelin is the option with an FDA label and trial results. For other goals, such as muscle, recovery or anti-aging, neither has been shown to work, and tesamorelin is not approved for them. Some people stack tesamorelin with ipamorelin; that pairing is also untested, as our tesamorelin and ipamorelin guide explains. For a single-peptide comparison, see ipamorelin vs tesamorelin.
Questions to ask a clinician
- What is my goal, and is either option approved or tested for it?
- If tesamorelin, will you check my IGF-1 and blood sugar, and for how long should I try it?
- If CJC-1295/ipamorelin, what evidence supports the dose, and how is the product’s identity confirmed?
- What happens to any benefit when I stop?
